EXPERIENCE:
`
`
`LEON H. KIRCIK, MD
`1169 EASTERN PARKWAY, SUITE 2310
`LOUISVILLE, KY 40217
`502-456-2783
`
` Associate Clinical Professor of Dermatology
`Department of Dermatology
`Mount Sinai Medical Center
`New York, New York
`2008-Present
`
`Associate Clinical Professor of Dermatology
`Indiana University Medical Center
`Indianapolis, Indiana
`2005-Present
`
`DREAM
`Dermatology Graduates Reaching for Excellence and Achievement in the Practice of Medicine
`Dermatologues Realisant l’Excellence et l’Accomplissement en Medecine
`DREAM is a medical education meeting in Canada targeting young graduates of Dermatology training to
`prepare them for real life practice
`Founder
`2015-Present
`
`International Dermatology Education Foundation, Inc
`IDEF is a non-profit organization whose principal mission is to raise awareness and improve dermatology
`care all over the world especially in underserved areas through education
`President
`2013-Present
`
`American Academy of Dermatology
`Stars of Academy 2017
`Stars of Academy 2016
`
`The Journal of Clinical & Aesthetic Dermatology
`U.S. Editorial Board
`2009-Present
`
`Skin & Aging
`Editorial Board
`2008-Present
`
`Journal of Drugs in Dermatology
`Senior Associate Editor
`2008-Present
`
`Practical Dermatology
`Editorial Board
`2006-Present
`
`American Academy of Dermatology
`Practice Management Resources
`Starting and Marketing a Dermatology Practice
`For Group and Mutlispecialty Practices
`Starting and Marketing a Dermatology Practice
`For Solo Practices
`A Guide To HIPAA and HITECH for Dermatology
`
`
`
`
`1 of 61
`
`Almirall EXHIBIT 2056
`
`Amneal v. Almirall
`IPR2019-00207
`
`

`

`Clinical Laboratory Improvement Amendments (CLIA) for Dermatology
`Editorial Board
`2013-Present
`
`Case Report in Clinical Pathology
`Editorial Board
`2013-Present
`
`Medical Monitoring and Data Monitoring Committee
`Kamedis
`2017- present
`
`Merck
`2012-2013
`
`Ethica
`2013-2014
`
`
`SKIN SCIENCES, PLLC
`Medical Director
`Louisville, KY
`2016-Present
`
`DermResearch, PLLC
`Medical Director
`Louisville, KY
`2005-Present
`
`
`Physicians Skin Care, PLLC
`Medical Director
`Louisville, Kentucky
`2000-Present
`
`National Botox Training Center
`September 2002-Present
`
`ASDS Dermatologic Surgery Preceptorship Program
`July 2002-Present
`
`Consultant – Merck
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2012-present
`
`Consultant - Amgen
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2007-present
`
`Consultant – Allergan
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2006-present
`
`Consultant- Promius (Dr. Reddy’s Lab)
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2008-present
`
`Consultant – Taro
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2012-present
`
`
`
`
`2
`
`2 of 61
`
`

`

`Consultant – Galderma
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2008-present
`
`Consultant – Valeant
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2011-present
`
`Consultant – GSK, Stiefel
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2007-2011
`
`Consultant - Genentech
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2001-2008
`2010-present
`
`Consultant – Biogen
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2001-2003
`
`Consultant – J&J
`Assisting in Phase II-IV Clinical Trial Design & Marketing
`2006-2010
`
`Dermatology and STD Clinic
`Muscatatuck State and Developmental Disabilities
`Center of Southern Indiana
`North Vernon, Indiana
`August 2002-2005
`
`Surveyor
`Accreditation Association of Ambulatory Healthcare
`March 2000-2008
`
`Madison Dermatology, LLC
`Madison, Indiana
`May 1998-2005
`
`Mohs and Reconstructive Surgery Center of Staten Island
`Staten Island, New York
`February 1996-2005
`
`Dermatology and STD Clinic
`JN Adam Developmental Disabilities
`Center of Western New York
`Perrysburg, NY
`May 1992-May 1998
`
`Mohs Micrographic Surgery
`Dermatology and Cosmetic Surgery and Laser Unit
`Dermatology Associates
`Louisville, Kentucky
`February 1996-Feb. 1998
`
`Mohs Micrographic Surgery Unit Nalitt Cancer Center
`Staten Island University Hospital
`Staten Island, New York
`February 1995-December 1996
`
`Dermatology and STD Clinic
`
`
`
`3
`
`3 of 61
`
`

`

`Ryan Nena Community Health Center
`New York, New York
`February 1995-December 1996
`
`Assistant Clinical Professor of Dermatology
`SUNY Brooklyn Medical Center
`Brooklyn, New York
`June 1995-February 1996
`
`Dermatology and STD Clinic
`Montefiore Medical Center
`Riker’s Island Health Center
`July 1993-July 1994
`
`LICENSURE: New York, New Jersey, Wisconsin, Kentucky, Indiana, Virginia
`
`POSTGRADUATE
`EDUCATION
`
`
`
`
`
`University of Wisconsin
`Mohs Micrographic Surgery &
`Cutaneous Oncology Fellowship
`January 1994 - December 1994
`
`State University of New York
`Health Sciences Center at Buffalo
`Dermatology Faculty
`July 1993 - December 1993
`
`Board Certified - Dermatology
`December 1993
`
`
`State University of New York
`Health Sciences Center at Buffalo
`Dermatology, Chief Residency
`April 1992 - June 1993
`Dermatology, Residency
`July 1990 - March 1992
`
`New York Medical College
`Westchester County Medical Center
`Internal Medicine, Internship
`July 1989 - June 1990
`
`
`
`MEDICAL State University of New York
`EDUCATION
`Health Sciences Center at Brooklyn
`
`
`Degree:
`
`Honors:
`Alpha Omega Alpha
`Cum Laude
`
`
` Dean’s Letter of Recommendation for Outstanding Medical Student
` Dr. William and Raynore Engel Scholar
`
`M.D. May 1989
`
`
`UNDERGRADUATE
`EDUCATION:
`
`
`
`
`
`
`Degree:
`
`Honors:
`
`New York University, New York, New York
`Washington Square University College
`
`Bachelor of Arts - Chemistry, May 1985
`
`Phi Beta Kappa
`Magna Cum Laude
`Caducean Society
`
`
`
`4
`
`4 of 61
`
`

`

`Dean’s Honor List
`Lucy G. Moses Scholar
`The Best Chemistry Major Award, May 1985
`
`
` State University of New York
` Health Science Center at Buffalo
` Department of Dermatology
` 1993-1994
`
` Dean’s Task Force
` Medical Education
` State University of New York
` Health Sciences Center at Brooklyn
` 1987-1989
`
`Teaching Assistant, Organic Chemistry
`
`Chemistry Department
`
`New York University
`
`New York, New York
`
` 1984 – 1985
`
`
`
`
`Rusk Institute
`New York University Medical Center
`New York, New York
`1983 – 1984
`
`Pathology Department
`Beth Israel Medical Center
`New York, New York
`1981 - 1983
`
`
`
`
`
`
`PUBLICATIONS:
`
`
`
`Stein-Gold L, Kircik L, Draelos Z, et al. Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema
`Associated with Rosacea: Pooled Analysis of the Two Phase 3, 29-Day Randomized, Controlled REVEAL
`Trials
`J Drugs Dermatol. 2018;17(11):1201-1208
`
`Tanghetti E, Harper J, Baldwin H, Kircik L, Bai Z, Alvandi, N. Once-Daily Topical Dapsone Gel 7.5%:
`Effective for Acne Vulgaris Regardless of Baseline Lesion Count, With Superior Efficacy in Females
`J Drugs Dermatol. 2018;17(11):1192-1198
`
`Kircik L. et al. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment
`Of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial
`J Drugs Dermatol. 2018;17(1):97-105
`
`Hoffman L, Raymond I, Kircik L. Treatment of Signs and Symptoms (Pruritus) of Interdigital Tinea Pedis
`With Econazole Nitrate Foam, 1%
`J Drugs Dermatol. 2018;17(2):229-232
`
`Bhatia N, Kircik L. Clobetasol Emulsion Foam and Calcipotriene 0.005% Foam Combination Therapy
`For the Maintenance of Treatment Response in Patients with Moderate Plaque Psoriasis
`J Drugs Dermatol. 2018;17(3):342-346
`
`Gottlieb A, Gordon K, Hsu S, Elewski B, Eichenfield L, Kircik L, Rastogi S, Pillai R. Improvement in itch
`And other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials
`
`
`
`5
`
`5 of 61
`
`

`

`JEADV 2018, 32, 1305-1313
`
`Hashim P, Chen T, Harper J, Kircik L. The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment
`Of Facial Acne Vulgaris
`J Drugs Dermatol. 2018; 17(6):641-645
`
`Del Rosso J, Kircik L, Tanghetti E. Management of Truncal Acne Vulgaris with Topical Dapsone 7.5% Gel
`J Clin Aesthet Dermatol. 2018;11(8):45-50
`
`Hashim P, Chen T, Lebwohl M, Marangell L, Kircik L. What Lies Beneath the Face Value of a
`BOX WARNING: A Deeper Look at Brodalumab
`J Drugs Dermatol. 2018;17(8 suppl):s29-34
`
`Kircik L Depression? It’s the Disease NOT the Drug
`J Drugs Dermatol. 2018;17(8 suppl):s28
`
`Moore A, Green L, Bruce S, Sadick N, Tschen E, Kircik L, et al
`Once-Daily Oral Sarecycline 1.5mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris:
`Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials
`J Drugs Dermatol. 2018;17(9):987-996
`
`Day D, Burgess C, Kircik L. Assessing the Potential Role for Topical Melatonin in an Antiaging Skin
`Regimen
`J Drugs Dermatol. 2018;17(8):966-969
`
`Hoffman L, Bhatia N, Zeichner J, Kircik L. Topical Vehicle Formulations in the Treatment Of Acne
`J Drugs Dermatol 2018;17(6 suppl):s6-10
`
`Kircik L Vehicles Matter
`J Drugs Dermatol 2018;17(6 suppl):s4-5
`
`Quertermous J, Desai S, Harper J, Lebwohl M, Torres A, Kircik L. The Practice of Compounding,
`Associated Compounding Regulations, and the Impact on Dermatologists
`J Drugs Dermatol. 2018;17(7 suppl):s17-22
`
`Amar, L, Kircik L. Treatment of Moderate Acne Vulgaris in Ftizpatrick Skin Type V or VI: Efficacy
`and Tolerability of Fixed Combination Clindamycin Phosphate 1.2 Benzoyl Peroxide 3.75% Gel
`J Drugs Dermatol. 2018;17(10):1107-1112
`
`Tyring S, Kircik, L. Novel Tretinoin 0.05% Lotion for the Once Daily Treatment of Moderate to
`Severe Acne Vulgaris: Assessment of Efficacy and Safety in Patients Aged 9 and Older
`J Drugs Dermatol. 2018;17(10):1084-1091
`
`Sadick N, Callender V, Kircik L, Kogan S. New Insight Into the Pathophysiology of Hair Loss
`Trigger a Paradigm Shift in the Treatment Approach
`J Drugs Dermatol. 2017;16(11 suppl):s135-140
`
`Kircik L. A New Look at Pathogenesis of Hair Loss
`J Drugs Dermatol. 2017;16(11 suppl):s133-134
`
`Hoffman L, Kircik L. Efficacy and Safety of Desoximetasone 0.25% Spray in Adult Atopic Dermatitis
`Subjects: Pilot Study. j Drugs Dermatol. 2017;16(9):919-922
`
`Hashim P, Nia J, Terrano D, Goldenberg G, Kircik L. A Comparative Study to Evaluate Epidermal Barrier
`Integrity of Psoriasis Patients Treated With Calcipotriene/Betamethasone Topical Suspension Versus
`Betamethasone Dipropionate 0.05% Lotion. J Drugs Dermatol. 2017;16(8):747-752
`
`Kircik L. Psoriasis Is a Chronic Disease: Long Term Efficacy and Safety of New Biologics Is Important
`J Drugs Dermatol 2017;16(8)suppl 1:s113-114
`
`Hashim P, Lebwohl M, Kircik L, Secukinumab: Long-Term Safety and Efficacy in Psoriasis
`
`
`
`6
`
`6 of 61
`
`

`

`J Drugs Dermatol 2017;16(8)suppl 1:s115-117
`
`Baldwin H, Stein-Gold L, Kircik L. Study Results in Focus: Assessing the Clinical Efficacy of Epiduo®
`Forte Gel. Practical Dermatology insert 2017;14(8)
`
`Baldwin H, Stein-Gold L, Kircik L. Advances in Acne Vulgaris Treatment. Practical Dermatology insert 2017
`
`Kircik L. Fixed Combination of Clindamycin Phosphate 1.2% and Benzoyl Peroxide 3.75% Aqueous Gel:
`Long-Term Use in Adult Females With Moderate Acne Vulgaris. J Drugs Dermatol. 2017;16(6):543-546
`
`Hoffman L, Del Rosso J, Kircik L. The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of
`Truncal Acne Vulgaris. J Drugs Dermatol. 2017;16(6):534-538
`
`Kircik L, Novas abordagens em acne. Derma Highlights & Science 2017;1(3):4-5
`
`Bhatia N, Berman B, Ceilley R, Kircik L. Understanding the Role of Photolyases: Photoprotection and Beyond
`J Drugs Dermatol. 2017;16(5 suppl):s61-66
`
`Kircik L. Delivery Technologies Matter: Maximizing Efficacy and Minimizing Side Effects
`J Drugs Dermatol 2017;16(suppl 3):s47
`
`Kircik L, Sung J, Stein-Gold L, Goldenberg, G. United States Food and Drug Administration Product
`Label Changes J Clin Aesthet Dermatol. 2017;10(2):20-29
`
`Kircik L, Okumu F, Kandavilli S, Sugarman J. Rational Vehicle Design Ensures Targeted
`Cutaneous Steroid Delivery. J Clin Aesthet Dermatol. 2017;10(2):12-19
`
`Del Rosso J, Kircik L. Spotlight on the Use of Nitric Oxide in Dermatology: What is it? What Does it Do?
`Can it Become an Important Addition to the Treatment Armamentarium for Skin Disease?
`J Drugs Dermatol. 2017;16(1suppl 1):s4-10
`
`Kircik L, Fowler J, Weiss J, Meng X, Guana A, Nyirady J. Efficacy of Secukinumab for Moderate-to-Severe
`Head and Neck Psoriasis Over 52 Weeks: Pooled Analysis of Four Phase 3 Studies
`Dermatol Ther (Heidelb) (2016)6:627
`
`Kircik L,. Evidence-Based Skincare: The Importance of Offering Moisturization, Relief, and
`Protection in Common Skin Disorders. J Drugs Dermatol. 2016;15(suppl 11):s76
`
`Mordorski B, Friedman A, Kircik L. Bensal HP for Second Intention Healing Following Mohs
`Micrographic Surgery or Shave Skin Biopsy: An Open-label Pilot Study
`J Drugs Dermatol. 2016;15(10):611-616
`
`Thiboutot D, Kircik L, McMichael A, Cook-Bolden F, Tyring S, Berk D, Chang-Lin J, Lin V, Kaoukhov, A
`Efficacy, Safety, and Dermal Tolerability of Dapsone Gel, 7.5% in Patients with Moderate
`Acne Vulgaris: A Pooled Analysis of Two Phase 3 Trials. J Clin Aesthet Dermatol 2016;9(10):18-27
`
`Del Rosso, J Kircik, L. Oral Apremilast for the Treatment of Plaque Psoriasis.
`J Clin Aesthet Dermatol. 2016;9(9):43-48.)
`
`Goldenberg A, Mousdicas N, Silverberg N, Powell D, Pelletier J, Silverberg J, Zippin J, Fonacier J,
`Totsi A, Lawley L, Wu Chang M, Scheman A, Kleiner G, Williams J, Watsky K, Dunnick C, Frederickson R,
`Matiz C, Chaney K, Estes T, Botto N, Draper M, Kircik, L Lugo-Somolinos A, Machler B, Jacob S.
`Pediatric Contact Dermatitis Registry Inaugural Case Data. DERMATITS, Vol 27, No 5 September/October 2016
`
`Kircik, L. Importance of Vehicles in Topical Treatment of Fungal Infections.
`Clin Podiatr Med Surg 33 (2016) 385-395
`
`Armstrong A, Papp K, Kircik L. Secukinumab Review of Clinical Evidence from the Pivotal Studies
`ERASURE, FIXTURE, and CLEAR. J Clin Aesthet Dermatol. 2016;9(6 suppl):S1-S12
`
`Kircik L, New Age of Biologics. J Clin Aesthet Dermatol. 2016;9(6 suppl):S1-S12
`
`
`
`7
`
`7 of 61
`
`

`

`
`Elewski B, Gupta A, Rosen T, Caldwell B, Pariser D, Kircik L, Bhatia N, Totsi A. Onychomycosis: Does
`Cure Equate to Treatment Success. J Drugs Dermatol. 2016;15(5):626-632
`
`Kircik L, Del Rosso J, Layton A, Schauber J. Over 25 Years of Clinical Experience with Ivermectin: An
`Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol. 2016;15(3):325-332
`
`Gupta A, Elewski B, Rosen T, Caldwell B, Pariser D, Kircik L, Bhatia N, Tosti A.
`Onychomycosis: Strategies to Minimize Recurrence. J Drugs Dermatol. 2016;15(3):279-282
`
`Zane L, Kircik L, Call R, Tschen E, Draelos D, Chanda S, Van Syoc M, Hebert A. Crisaborole
`Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b,
`Open-Label, Maximal-Use Systemic Exposure Study. Pediatric Dermatology 1-8, 2016
`
`Krueger JG, Kircik L, Hougier F, Friedman A, You X, Lucas N, Greenberg SJ, Sweetser M, Castro-Borrero W,
`McCroskery P, Elkins J. Cutaneous Adverse Events in the Randomized, Double-Blind, Active Comparator
`DECIDE Study of Daclizumab HYP Versus Intramuscular Interferon Beta-1a in Patients with
`Relapsing-Remitting Multiple Sclerosis. Adv Ther. 2016;33(7):1231-45
`
`Kircik L, Krueger J, Hougier F, Friedman A, Lucas N, Elkins J, McCroskery P. Incidence, Severity,
`Duration, and Treatment of Cutaneous Adverse Events in the DECIDE Study of
`Daclizumab HYP Versus Intramuscular Interferon Beta-1a in Patients with Relapsing-Remitting Multiple
`Sclerosis. Presented at Societa Italiana di Neurologica – 2016 Congresso: October 25, 2016; Venice Italy
`
`Kircik L, Krueger J, Hougier F, Friedman A, Lucas N, Castro-Borerro W, McCroskery P,
`Elkins J. Incidence, Severity, Duration, and Treatment of Cutaneous Adverse Events in the DECIDE Study of
`Daclizumab HYP Versus Intramuscular Interferon Beta-1a in Patients with Relapsing-Remitting Multiple
`Sclerosis. Presented at Deutschen Gesellschaft fur Neurologie – 89th Jahreskongress; September 23, 2016;
`Mannheim, Germany.
`
`Kircik, L. Use of Dapsone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of
`Oral Doxycycline and Dapsone 5% Gel Combination Treatment. J Drugs Dermatol. 2016;15(2):611-615
`
`Kircik L, Bhatt V, Martin G, Pillai, R. Randomized, Double-blind, Split-face Study to Compare the
`Irritation Potential of Two Topical Acne Formulations Over a 21-Day Treatment Period.
`J Drugs Dermatol. 2016;15(2):611-615
`
`Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J., Puig L, Papp L, Spelman L, Toth D,
`Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T,
`Paul C, Lacour JP, Tyring S, Kircik L, et al. Phase 3 studies comparing Brodalumab with Ustekinumab in
`Psoriais. N Engl J Med 2015;373:1318-28
`
`Kircik L, Krueger J, Hougier F, Friedman A, You X, Lucas N, Sweetser M, Castro-Borrero W, McCroskery P,
`Elkins J. Incidence, Severity, Duration, and Treatment of Cutaneous Adverse Events in the DECIDE Study of
`Daclizumab HYP Versus Intramuscular Interferon Beta-1a in Patients with Relapsing-Remitting Multiple
`Sclerosis. Presented at European Committee for Treatment & Research in Multiple Sclerosis – 31st
`Congress; October 8, 2015; Barcelona, Spain. P550
`
`
`1: Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens
`RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Apremilast, an oral
`phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque
`psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and
`Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am
`Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049. PubMed
`PMID: 26089047.
`
`2: Eichenfield LF, Del Rosso JQ, Mancini AJ, Cook-Bolden F, Stein Gold L, Desai
`S, Weiss J, Pariser D, Zeichner J, Bhatia N, Kircik L. Evolving perspectives on
`the etiology and pathogenesis of acne vulgaris. J Drugs Dermatol. 2015
`Mar;14(3):263-72. PubMed PMID: 25738848.
`
`
`
`8
`
`8 of 61
`
`

`

`
`3: Rosen T, Friedlander SF, Kircik L, Zirwas MJ, Stein Gold L, Bhatia N, Gupta
`AK. Onychomycosis: epidemiology, diagnosis, and treatment in a changing
`landscape. J Drugs Dermatol. 2015 Mar;14(3):223-33. PubMed PMID: 25738843.
`
`4: Del Rosso JQ, Kircik L, Gallagher CJ. Comparative efficacy and tolerability of
`dapsone 5% gel in adult versus adolescent females with acne vulgaris. J Clin
`Aesthet Dermatol. 2015 Jan;8(1):31-7. PubMed PMID: 25610522; PubMed Central
`PMCID: PMC4295856.
`
`5: Del Rosso JQ, Kircik LH. Update on the management of rosacea: a status report
`on the current role and new horizons with topical azelaic acid. J Drugs Dermatol.
`2014 Dec;13(12):s101-7. PubMed PMID: 25607798.
`
`6: Kircik LH. Challenges and advances in rosacea management. J Drugs Dermatol.
`2014 Dec;13(12):s100. PubMed PMID: 25607797.
`
`7: Kircik LH. Effect of skin barrier emulsion cream vs a conventional moisturizer
`on transepidermal water loss and corneometry in atopic dermatitis: a pilot study.
`J Drugs Dermatol. 2014 Dec;13(12):1482-4. PubMed PMID: 25607793.
`
`8: Kircik LH. Enhancing transungual delivery and spreading of efinaconazole under
`the nail plate through a unique formulation approach. J Drugs Dermatol. 2014
`Dec;13(12):1457-61. PubMed PMID: 25607788.
`
`9: Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A,
`Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase
`3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in
`treating inflammatory lesions of rosacea: results of two 40-week controlled,
`investigator-blinded trials. J Drugs Dermatol. 2014 Nov;13(11):1380-6. PubMed
`PMID: 25607706.
`
`10: Del Rosso JQ, Kircik L, Goldenberg G, Brian B. Comprehensive management of
`actinic keratoses: practical integration of available therapies with a review of
`a newer treatment approach. J Clin Aesthet Dermatol. 2014 Sep;7(9 Suppl
`S2-S12):S2-S12. PubMed PMID: 25302088; PubMed Central PMCID: PMC4187997.
`
`11: Bowe WP, Kircik LH. The importance of photoprotection and moisturization in
`treating acne vulgaris. J Drugs Dermatol. 2014 Aug;13(8):s89-94. PubMed PMID:
`25116982.
`
`12: Kircik LH. Why do we need another moisturizer for our acne patients? J Drugs
`Dermatol. 2014 Aug;13(8):s88. PubMed PMID: 25116981.
`
`13: Del Rosso JQ, Kircik LH. Transitioning from brand to generic with topical
`products and the importance of maintaining the formulation and therapeutic
`profiles of the original product: focus on clocortolone pivalate 0.1% cream. J
`Drugs Dermatol. 2014 Jul;13(7):s77-83. PubMed PMID: 25007376.
`
`14: Kircik LH. Understanding generics. J Drugs Dermatol. 2014 Jul;13(7):s75-6.
`PubMed PMID: 25007375.
`
`15: Kircik LH. Re-evaluating treatment targets in acne vulgaris: adapting to a
`new understanding of pathophysiology. J Drugs Dermatol. 2014 Jun;13(6):s57-60.
`PubMed PMID: 24918572.
`
`16: Kircik LH. Evolving concepts in the pathogenesis of acne vulgaris. J Drugs
`Dermatol. 2014 Jun;13(6):s56. PubMed PMID: 24918571.
`
`17: Kircik L. The effect of desonide hydrogel on pruritis associated with atopic
`dermatitis. J Drugs Dermatol. 2014 Jun;13(6):725-8. PubMed PMID: 24918564.
`
`
`
`9
`
`9 of 61
`
`

`

`
`18: Kircik LH. A study to assess the occlusivity and moisturization potential of
`three topical corticosteroid products using the skin trauma after razor shaving
`(STARS) bioassay. J Drugs Dermatol. 2014 May;13(5):582-5. PubMed PMID: 24809882.
`
`19: Kircik LH. Evaluating tretinoin formulations in the treatment of acne. J
`Drugs Dermatol. 2014 Apr;13(4):466-70. Review. PubMed PMID: 24719067.
`
`20: Routt ET, Jim SC, Zeichner JA, Kircik LH. What is new in fungal
`pharmacotherapeutics? J Drugs Dermatol. 2014 Apr;13(4):391-5; quiz 396. Review.
`PubMed PMID: 24719057.
`
`21: Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, Appell M,
`Steinhoff M, Lynde C, Liu H, Jacovella J. Efficacy and safety of ivermectin 1%
`cream in treatment of papulopustular rosacea: results of two randomized,
`double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014
`Mar;13(3):316-23. PubMed PMID: 24595578.
`
`22: Kircik LH, Onumah N. Use of naftifine hydrochloride 2% cream and 39% urea
`cream in the treatment of tinea pedis complicated by hyperkeratosis. J Drugs
`Dermatol. 2014 Feb;13(2):162-5. PubMed PMID: 24509966.
`
`23: Sigurgeirsson B, Kircik L, Nemoto O, Mikazans I, Haemmerle S, Thurston HJ,
`Papavassilis C, Richards HB. Secukinumab improves the signs and symptoms of
`moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or
`feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2
`dose-ranging study. J Eur Acad Dermatol Venereol. 2014 Aug;28(8):1127-9. doi:
`10.1111/jdv.12343. Epub 2013 Dec 13. PubMed PMID: 24330415.
`
`24: Kircik L, Lebwohl MG, Del Rosso JQ, Bagel J, Stein Gold L, Weiss JS. Clinical
`study results of desoximetasone spray, 0.25% in moderate to severe plaque
`psoriasis. J Drugs Dermatol. 2013 Dec;12(12):1404-10. PubMed PMID: 24301242.
`
`25: Kircik LH. Put your best foot forward: advances in the management of tinea
`pedis. J Drugs Dermatol. 2013 Nov;12(11 Suppl):s164. PubMed PMID: 24212411.
`
`26: Del Rosso JQ, Kircik LH. Optimizing topical antifungal therapy for
`superficial cutaneous fungal infections: focus on topical naftifine for cutaneous
`dermatophytosis. J Drugs Dermatol. 2013 Nov;12(11 Suppl):s165-71. Review. PubMed
`PMID: 24196340.
`
`27: Kircik LH. The microsponge delivery system reduces facial oiliness and shine
`during acne therapy. J Drugs Dermatol. 2013 Nov;12(11):1268-70. PubMed PMID:
`24196335.
`
`28: Onumah N, Kircik L. Pimecrolimus cream and Tacrolimus ointment in the
`treatment of atopic dermatitis: a pilot study on patient preference. J Drugs
`Dermatol. 2013 Oct;12(10):1145-8. PubMed PMID: 24085050.
`
`29: Kircik L, Hougeir F, Bikowski J. Atopic dermatitis, and the role for a
`ceramide-dominant, physiologic lipid-based barrier repair emulsion. J Drugs
`Dermatol. 2013 Sep;12(9):1024-7. Review. PubMed PMID: 24002150.
`
`30: Del Rosso JQ, Kircik LH. The sequence of inflammation, relevant biomarkers,
`and the pathogenesis of acne vulgaris: what does recent research show and what
`does it mean to the clinician? J Drugs Dermatol. 2013 Aug;12(8 Suppl):s109-15.
`Review. PubMed PMID: 23986176.
`
`31: Kircik LH. Do we really need topical antibiotics in our new treatment
`paradigm of acne vulgaris? A novel question to consider based on an updated model
`of pathogenesis. J Drugs Dermatol. 2013 Aug;12(8 Suppl):s107. PubMed PMID:
`
`
`
`10
`
`10 of 61
`
`

`

`
`23986174.
`
`32: Stein Gold LF, Parish LC, Vlahovic T, Plaum S, Kircik L, Fleischer AB Jr,
`Verma A, Olayinka B, Hardas B. Efficacy and safety of naftifine HCl Gel 2% in the
`treatment of interdigital and moccasin type tinea pedis: pooled results from two
`multicenter, randomized, double-blind, vehicle-controlled trials. J Drugs
`Dermatol. 2013 Aug;12(8):911-8. PubMed PMID: 23986165.
`
`33: Del Rosso JQ, Kircik LH. The integration of physiologically-targeted skin
`care in the management of atopic dermatitis: focus on the use of a cleanser and
`moisturizer system incorporating a ceramide precursor, filaggrin degradation
`products, and specific "skin-barrier-friendly" excipients. J Drugs Dermatol. 2013
`Jul 1;12(7):s85-91. PubMed PMID: 23884506.
`
`34: Kircik LH. Over-the-counter product role in the daily management of atopic
`dermatitis: achieving success with advanced technology. J Drugs Dermatol. 2013
`Jul 1;12(7):s84. PubMed PMID: 23884505.
`
`35: Kircik LH. The role of benzoyl peroxide in the new treatment paradigm for
`acne. J Drugs Dermatol. 2013 Jun 1;12(6):s73-6. PubMed PMID: 23839205.
`
`36: Leyden JJ, Bruce S, Lee CS, Ling M, Sheth PB, Stewart DM, Werschler WP,
`Gilbert RD, Kircik L. A randomized, phase 2, dose-ranging study in the treatment
`of moderate to severe inflammatory facial acne vulgaris with doxycycline calcium.
`J Drugs Dermatol. 2013 Jun 1;12(6):658-63. PubMed PMID: 23839182.
`
`37: Kircik LH, Dickerson JE Jr, Kitten C, Weedon KA, Slade HB. Allogeneic growth
`arrested keratinocytes and fibroblasts delivered in a fibrin spray accelerate
`healing in Mohs micrographic surgery wounds. J Drugs Dermatol. 2013
`May;12(5):558-61. PubMed PMID: 23652951.
`
`38: Gold MH, Kircik LH, Bucay VW, Kiripolsky MG, Biron JA. Treatment of facial
`photodamage using a novel retinol formulation. J Drugs Dermatol. 2013
`May;12(5):533-40. PubMed PMID: 23652947.
`
`39: David E, Tanuos H, Sullivan T, Yan A, Kircik LH. A double-blind,
`placebo-controlled pilot study to estimate the efficacy and tolerability of a
`nonsteroidal cream for the treatment of cradle cap (seborrheic dermatitis). J
`Drugs Dermatol. 2013 Apr;12(4):448-52. PubMed PMID: 23652893.
`
`40: Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D,
`Thompson EH, Yang J, Kricorian G, Koo J. A randomized study to evaluate the
`efficacy and safety of adding topical therapy to etanercept in patients with
`moderate to severe plaque psoriasis. J Am Acad Dermatol. 2013 Sep;69(3):385-92.
`doi: 10.1016/j.jaad.2013.03.031. Epub 2013 May 1. PubMed PMID: 23643256.
`
`41: Del Rosso JQ, Kircik LH. Not all topical corticosteroids are created equal!
`Optimizing therapeutic outcomes through better understanding of vehicle
`formulations, compound selection,and methods of application. J Drugs Dermatol.
`2012 Dec;11(12):s5-8. PubMed PMID: 23547332.
`
`42: Kircik LH. Practical aspects of topical corticosteroid selection. J Drugs
`Dermatol. 2012 Dec;11(12):s3-4. PubMed PMID: 23547331.
`
`43: Kircik LH. The only topical retinoid without a generic alternative:
`tazarotene. J Drugs Dermatol. 2013 Mar;12(3):s52. PubMed PMID: 23545934.
`
`44: Kircik LH, Eastman WJ, Gwazdauskas J. A randomized, double-blind phase 4
`study of the efficacy and safety of ethanol-free clobetasol propionate foam,
`0.05%, vs vehicle foam in the treatment of chronic hand dermatitis. J Drugs
`
`
`
`11
`
`11 of 61
`
`

`

`Dermatol. 2013 Mar;12(3):328-34. PubMed PMID: 23545917.
`
`
`45: Jackson JM, Kircik LH, Lorenz DJ. Efficacy of extended-release 45 mg oral
`minocycline and extended-release 45 mg oral minocycline plus 15% azelaic acid in
`the treatment of acne rosacea. J Drugs Dermatol. 2013 Mar;12(3):292-8. PubMed
`PMID: 23545911.
`
`46: Kircik LH, Gwazdauskas J, Butners V, Eastern J, Green LJ. Evaluation of the
`efficacy, tolerability, and safety of an over-the-counter acne regimen containing
`benzoyl peroxide and salicylic acid in subjects with acne. J Drugs Dermatol. 2013
`Mar;12(3):259-64. PubMed PMID: 23545906.
`
`47: Del Rosso JQ, Kircik LH. The role of a midpotency topical corticosteroid and
`the clinical relevance of formulation characteristics in the management of
`commonly encountered eczematous and inflammatory dermatoses in adults and
`children: focus on the pharmacologic properties of clocortolone pivalate 0.1%
`cream. J Drugs Dermatol. 2013 Feb;12(2):s5-s10. PubMed PMID: 23377405.
`
`48: Kircik LH. Clocortolone pivalate: a topical corticosteroid with a unique
`structure. J Drugs Dermatol. 2013 Feb;12(2):s3-4. PubMed PMID: 23377404.
`
`49: Green L, Kircik LH, Gwazdauskas J. Randomized, controlled, evaluator-blinded
`studies conducted to compare the efficacy and tolerability of 3 over-the-counter
`acne regimens in subjects with mild or moderate acne. J Drugs Dermatol. 2013
`Feb;12(2):180-5. PubMed PMID: 23377391.
`
`50: Kircik LH. Comparative study of the efficacy and tolerability of a unique
`topical scar product vs white petrolatum following shave biopsies. J Drugs
`Dermatol. 2013 Jan;12(1):86-90. PubMed PMID: 23377333.
`
`51: Kircik LH. Histologic improvement in photodamage after 12 months of treatment
`with tretinoin emollient cream (0.02%). J Drugs Dermatol. 2012 Sep;11(9):1036-40.
`PubMed PMID: 23135644.
`
`52: Kircik LH, Del Rosso JQ. The treatment of inflammatory facial dermatoses with
`topical corticosteroids: focus on clocortolone pivalate 0.1% cream. J Drugs
`Dermatol. 2012 Oct;11(10):1194-8. PubMed PMID: 23134984.
`
`53: Hougeir FG, Kircik L. A review of delivery systems in cosmetics. Dermatol
`Ther. 2012 May-Jun;25(3):234-7. doi: 10.1111/j.1529-8019.2012.01501.x. Review.
`PubMed PMID: 22913440.
`
`54: Kircik L, Jones TM, Jarratt M, Flack MR, Ijzerman M, Ciotti S, Sutcliffe J,
`Boivin G, Stanberry LR, Baker JR; NB-001 Study Group. Treatment with a novel
`topical nanoemulsion (NB-001) speeds time to healing of recurrent cold sores. J
`Drugs Dermatol. 2012 Aug;11(8):970-7. PubMed PMID: 22859243.
`
`55: Del Rosso JQ, Kircik L. A Comprehensive Review of Clocortolone Pivalate 0.1%
`Cream: Structural Development, Formulation Characteristics, and Studies
`Supporting Treatment of Corticosteroid-responsive Dermatoses. J Clin Aesthet
`Dermatol. 2012 Jul;5(7):20-4. PubMed PMID: 22798972; PubMed Central PMCID:
`PMC3396454.
`
`56: Kircik LH. Efficacy and tolerability of retapamulin 1% ointment for the
`treatment of infected atopic dermatitis: a pilot study. J Drugs Dermatol. 2012
`Jul;11(7):858-60. PubMed PMID: 22777229.
`
`57: Kircik LH, Dahl A, Yatskayer M, Raab S, Oresajo C. Safety and efficacy of two
`anti-acne/anti-aging treatments in subjects with photodamaged skin and mild to
`moderate acne vulgaris. J Drugs Dermatol. 2012 Jun;11(6):737-40. PubMed PMID:
`
`
`
`12
`
`12 of 61
`
`

`

`22648221.
`
`58: Del Rosso JQ, Gallo RL, Kircik L, Thiboutot D, Baldwin HE, Cohen D. Why is
`rosacea considered to be an inflammatory disorder? The primary role, clinical
`
`relevance, and therapeutic correlations of abnormal innate immune response in
`rosacea-prone skin. J Drugs Dermatol. 2012 Jun;11(6):694-700. Review. PubMed
`PMID: 22648215.
`
`59: Onumah N, Kircik LH. Psoriasis and its comorbidities. J Drugs Dermatol. 2012
`May;11(5 Suppl):s5-10. Review. PubMed PMID: 22644770.
`
`60: Kircik LH. Letter from the guest editor. J Drugs Dermatol. 2012 May;11(5
`Suppl):s4. PubMed PMID: 22644769.
`
`61: Kircik LH. Transepidermal water loss (TEWL) and corneometry with hydrogel
`vehicle in the treatment of atopic dermatitis: a randomized, investigator-blind
`pilot study. J Drugs Dermatol. 2012 Feb;11(2):180-4. PubMed PMID: 222701